Lord's

Lord's Mark Industries Limited

Reg. Add.: B-101 Riddhi Siddhi Complex, M.G. Road, Borivali (E), Mumbai - 400 066
Corp. Add.: 201, 2nd Floor, Dosti Pinnacle, Above New Passport Office, Road No. 22, Wagle Estate, Thane West, Maharashtra - 400604.
Tel.: 022 44504923, Email: info@lordsmark.com, compliances@lordsmark.com
Website: www.lordsmark.com, CIN No.: L35103MH1979PLC021614

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Date : 24.08.2026

Scrip Code: 501261

Subject: Disclosure regarding Strategic Collaboration with ARKALL Holdings Limited for Healthcare Expansion across the Caribbean Region

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Lords Mark Industries Limited ("the Company") has entered into a strategic collaboration with ARKALL Holdings Limited, a Caribbean-based partner, for establishing and operating pathology laboratories and facilitating the commercialisation of the Company's medical devices, medical equipment, diagnostics and healthcare portfolio across the Caribbean region.

The collaboration represents the Company's proposed entry into the Caribbean healthcare market and is intended to be implemented through a phased expansion model, commencing with Trinidad & Tobago and progressively extending to other Caribbean markets over the next three years.

Key Features of the Collaboration

- ARKALL Holdings Limited will undertake the investments required for the proposed Caribbean expansion, including investments towards establishing and scaling pathology laboratory operations and supporting commercialisation activities.
- Lords Mark Industries Limited will provide its range of IVD products, rapid test kits, biochemistry reagents, pathology laboratory products, medical equipment, dialysis machines and other healthcare solutions.
- The Company will provide technical guidance, product knowledge, training and operational support as may be required.

- ARKALL Holdings Limited will lead commercialisation and market development activities across the agreed Caribbean markets.
- The parties will initially undertake market assessment and business planning for Trinidad & Tobago, following which the expansion roadmap will be progressively implemented across the wider Caribbean region.
- The Company will also provide technical and product-related documentation and support for applicable product registrations and regulatory processes.

The proposed collaboration is expected to create a scalable healthcare platform combining pathology and diagnostics infrastructure with access to medical technology and equipment.

Based on the Company's current internal projections and business planning assessment, Lords Mark Industries Limited expects the proposed phased Caribbean rollout to have the potential to generate approximately US$100 million in export revenue between FY 2026-27 and FY 2030-31, subject to successful implementation, regulatory approvals, market penetration and other commercial factors.

Further, based on the Company's internal assessment, the indicative pathology and diagnostics opportunity across the identified Caribbean markets is estimated at approximately US$1.24 billion. The actual business opportunity and revenue realisation will depend upon market conditions, regulatory approvals, execution and the pace of expansion.

The Company clarifies that the above revenue projections and market opportunity estimates are forward-looking statements and internal management assessments, and actual results may vary materially depending on various business, regulatory, market and other factors.

Dr. Sachidanand Upadhyay, Managing Director & CEO, Lords Mark Industries Limited, said:

"Our collaboration with ARKALL Holdings Limited marks an important step in taking Lord's Mark's healthcare and MedTech capabilities to a wider international market. The Caribbean expansion will allow us to combine our medical technology, pathology and dialysis capabilities with ARKALL's regional commercial presence. We see this partnership as a long-term platform for expanding our export footprint while contributing to the development of accessible and technology-enabled healthcare infrastructure across the region."

A Senior Management Representative of ARKALL Holdings Limited said:

"The Caribbean presents an important opportunity to strengthen healthcare infrastructure through greater access to quality diagnostics, medical technology and specialised healthcare solutions. Our partnership with Lord's Mark Industries Ltd brings together local market capabilities with an expanding portfolio of healthcare technologies. Beginning with Trinidad & Tobago, our objective is to build a scalable network that can progressively serve healthcare needs across the Caribbean markets."

The Company will make further disclosures, as and when required, in accordance with the applicable provisions of the SEBI (LODR) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,
For Lord's Mark Industries Limited
(Formerly known as Lords Mark, India Limited and Kratos Energy & Infrastructure Limited)

LORD'S MARK INDUSTRIES LIMITED

Sachidanand Hariram Upadhyay
Chairman and Managing Director
DIN: 01631728

Annexure A

(Disclosure under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023)

Para No.	**Particulars**	**Details**
a)	Name of the entity with whom agreement is entered	**ARKALL Holdings Limited**
b)	Purpose / Object of the agreement	Strategic partnership to establish/operate pathology labs and commercialize IVD products, dialysis machines, and MedTech equipment across 28 Caribbean countries.
c)	Significant terms & conditions	**Funding:** 100% investment by ARKALL Holdings Limited. **Role of Lord's Mark:** Supply of IVD products, technical guidance, regulatory support, and training. **Role of ARKALL:** Market development, commercial operations, and lab execution.
d)	Market Rollout & Financial Scope	**Phase 1:** Trinidad & Tobago. **Expansion:** Phased rollout over 3 years across 28 markets. **Revenue Estimate:** ~US $100 million export revenue projected between FY27–FY31.

Para No.	Particulars	Details
e)	Whether related party transaction / Conflict of Interest	No. The promoter / promoter group has no interest in ARKALL Holdings Limited.